Effect of tumor burden on survival in patients with stage IV EGFR-mutant NSCLC receiving osimertinib monotherapy

被引：0
|
作者：
Delasos, Lukas
Berube, Bryan
Nikoo, Maedeh Zokaei
Wei, Wei
Shapiro, Marc A.
Hassan, Khaled Aref
Stevenson, James
Adjei, Alex A.
Pennell, Nathan A.
机构：
[1] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH USA
[2] Cleveland Clin, Cleveland, OH USA
[3] Cleveland Clin Fdn, Cleveland, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8611
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
    Kian, W.
    Roisman, L. C.
    Dudnik, J.
    Chernomordikov, L.
    Allen, A. M.
    Corn, B.
    Dudnik, E.
    Rosenberg, S. K.
    Zemel, M.
    Lavrenkov, K.
    Peled, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S941 - S941
  • [2] Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
    Ye, Qiuyue
    Xu, Yan
    Zhao, Jing
    Gao, Xiaoxing
    Chen, Minjiang
    Pan, Ruili
    Zhong, Wei
    Wang, Mengzhao
    TRANSLATIONAL ONCOLOGY, 2023, 31
  • [3] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
  • [4] Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
    Kuang, Linwu
    Zhang, Yuchen
    Wang, Hao
    Wang, Peng
    Li, Yangkai
    BMC PULMONARY MEDICINE, 2025, 25 (01):
  • [5] Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC
    Piotrowska, Zofia
    Liu, Stephen V.
    Muzikansky, Alona
    Marcoux, Nicolas
    Banwait, Mandeep
    Stevens, Sara
    Goodwin, Kelly
    Lafferty, Tracey E.
    Ackil, Jennifer
    Krueger, Elizabeth A.
    Heist, Rebecca Suk
    Lin, Jessica Jiyeong
    Gainor, Justin F.
    Hata, Aaron N.
    Shaw, Alice Tsang
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Osimertinib in EGFR-mutant NSCLC: how to select patients and when to treat
    Zugazagoitia, Jon
    Ferrer, Irene
    Paz-Ares, Luis
    LANCET ONCOLOGY, 2016, 17 (12): : 1622 - 1623
  • [7] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [8] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
    White, Maya N.
    Piotrowska, Zofia
    Stirling, Kevin
    Liu, Stephen V.
    Banwait, Mandeep K.
    Cunanan, Kristen
    Sequist, Lecia V.
    Wakelee, Heather A.
    Hausrath, Daniel
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
  • [9] Osimertinib Called "Home Run" for EGFR-Mutant NSCLC
    Rose, Suzanne
    CANCER DISCOVERY, 2020, 10 (07) : 896 - 897
  • [10] Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
    Remon, J.
    Steuer, C. E.
    Ramalingam, S. S.
    Felip, E.
    ANNALS OF ONCOLOGY, 2018, 29 : I20 - I27
12345